(1)
- Orismilast is a next generation oral PDE4-inhibitor with an improved therapeutic window compared to other PDE4-inhibitors
- Oral orismilast (UNI50001) has demonstrated proof of concept in patients living with plaque psoriasis and indicated best-in-class potential
- PDE4-inhibition is a validated pharmacological target published for a broad range of inflammatory indications
1
- The improved therapeutic window of orismilast suggests potential for use in a number of inflammatory conditions, which have so far been limited by the typical narrow therapeutic window of PDE4-inhibitors
HELLERUP, Denmark, Jan. 7, 2021 /PRNewswire/ UNION therapeutics A/S (UNION) today announces that the US Food and Drug Administration (FDA) has approved an Investigational New Drug program (IND) for oral orismilast; a next generation PDE4-inhibitor for the treatment of plaque psoriasis in adults.